On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale AgreementSM (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having an aggregate offering price of up to $50,000,000 (such amount to be in addition to the aggregate gross sales proceeds received by the Company from the sale of Common Stock prior to the date hereof pursuant to the 2025 Sale Agreement (as defined below)) (the “ATM Shares”). The 2026 Sales Agreement amends and restates that certain Amended and Restated Open Market Sale AgreementSM, dated as of August 14, 2025 (the “2025 Sales Agreement”), between the Company and Jefferies, which had a maximum aggregate offering price of up to $50,000,000. As of November 12, 2026, the Company had sold an aggregate of approximately $50,000,000 of ATM Shares under the 2025 Sales Agreement.
|
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for the treatment of solid tumors. The company utilizes two distinct platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs to induce systemic anti-tumor immune responses through in-situ immunization. Its lead product candidate, aglatimagene besadenovec (formerly CAN-2409), is an adenoviral gene therapy administered intratumorally in conjunction with the prodrug valacyclovir, currently in phase 3 trials for localized prostate cancer. A second candidate, linoserpaturev (CAN-3110), is a replication-competent HSV oncolytic virus designed for high-grade glioma. The company serves patients with solid tumors, including prostate, lung, and brain cancers, and has received FDA Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for aglatimagene. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage candeltx.com |
| Sector Healthcare | IR page ir.candeltx.com | |
|
Tags
viral immunotherapy, oncolytic viruses, gene therapy, prostate cancer, glioma, solid tumors, adenovirus, herpes simplex virus, intratumoral injection, clinical-stage, aglatimagene besadenovec, CAN-2409, linoserpaturev, CAN-3110, valacyclovir
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 818.976M |
| Market cap (USD) | $ 818.976M |
| P/E | -7.01 |
| PEG | — |
| P/BV | 6.22 |
| P/S | — |
| P/OCF | -11.89 |
| P/FCF | -11.67 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -64.6% |
| ROI | -38.5% |
| ROIC | -36.5% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 90.8% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 62 |
| Quality score | -78.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Borrowings, current (USD) | — | — | — | — | 8.89M | 9.9M | 0.00 |
| Borrowings, non-current (USD) | — | — | — | — | 11.6M | 1.73M | — |
| Lease liabilities (USD) | — | — | — | 1.95M | 1.49M | 973,000 | 1.9M |
| Cash and deposits (USD) | 5.45M | 35.1M | 82.6M | 70.1M | 35.4M | 103M | 120M |
| Right-of-use assets (USD) | — | — | — | 1.06M | 816,000 | 542,000 | 1.66M |
| Net debt (borrowings + leases - cash) (USD) | — | — | — | — | -13.4M | -90.1M | -118M |
| Cash flow detail | |||||||
| Operating cash flow (USD) | — | -9.07M | -22.2M | -31.4M | -34.2M | -27M | -38.3M |
| Purchases of property, plant and equipment (USD) | — | -1.48M | -1.84M | -1.3M | -457,000 | -16,000 | -587,000 |
| Change in payables (cash effect) (USD) | — | 289,000 | 669,000 | -1.21M | 45,000 | -185,000 | 802,000 |
| Interest paid (cash effect) (USD) | — | — | — | -1.15M | -2.15M | -1.8M | -1.28M |
| Income taxes paid (cash effect) (USD) | — | -93,000 | -29,000 | -183,000 | — | — | — |
| Share-based compensation (USD) | — | 2.11M | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Free cash flow (OCF - PPE - intangibles) (USD) | — | -10.5M | -24.1M | -32.7M | -34.7M | -27M | -38.9M |
| Income detail | |||||||
| Research and development expense (USD) | — | 8.75M | 15.2M | 20.8M | 24.5M | 19.3M | 30.5M |
| ↳ 5y CAGR | +28.4% | ||||||
| Total comprehensive income (USD) | — | -17.7M | -36.1M | — | — | — | — |
| Comprehensive income to owners (USD) | — | -17.7M | -36.1M | — | — | — | — |
| Reported | Sep 8, 2021 | Mar 29, 2022 | Mar 29, 2022 | Mar 30, 2023 | Mar 28, 2024 | Mar 13, 2025 | Mar 12, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
On November 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Oct 29, 2026
NEEDHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.
The presentation will feature longitudinal immune-profiling findings from PrTK05 (NCT07332000), together with biodistribution and viral shedding data, providing additional insights into the biological activity and characterization of aglatimagene in patients with localized intermediate-risk prostate cancer.
The poster presentation details are as follows:
Title: Longitudinal immune profiling in the PrTK05 trial of aglatimagene besadenovec plus valacyclovir with radiation therapy for localized intermediate-risk prostate cancer
Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
Abstract Number: 1172
Session Date: Saturday, November 7, 2026
Location: Phoenix Convention Center - North Building - Lower Level - Exhibition Halls 4, 5 and 6
About aglatimagene besadenovec
Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) with results published in the Journal for ImmunoTherapy of Cancer, and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform and is currently in an ongoing phase 3 clinical trial in NSCLC. Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Candel Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.